| Market Capitalization (Millions $) |
288 |
| Shares
Outstanding (Millions) |
70 |
| Employees |
288 |
| Revenues (TTM) (Millions $) |
64 |
| Net Income (TTM) (Millions $) |
-219 |
| Cash Flow (TTM) (Millions $) |
-233 |
| Capital Exp. (TTM) (Millions $) |
2 |
Business Description
Bicycle Therapeutics Plc is a biotechnology company that specializes in the development of small molecule drugs based on its proprietary Bicycle technology platform. The company is based in the United Kingdom and was founded in 2009.
Bicycle Therapeutics' technology platform is focused on designing and developing bicyclic peptides, which are small and highly specific molecules that can target and bind to disease-causing proteins. These peptides are derived from natural molecules such as hormones and can be modified to enhance their properties.
The company's lead product candidate, BT1718, is being developed for the treatment of solid tumors. BT1718 is a bicyclic peptide-drug conjugate that selectively targets tumors while sparing healthy tissues, potentially reducing side effects associated with chemotherapy.
Bicycle Therapeutics has also entered into partnerships and collaborations with other pharmaceutical companies to further develop its technology platform and advance its pipeline of drug candidates. These partnerships include collaborations with AstraZeneca, Bioverativ, and Cancer Research UK.
Overall, Bicycle Therapeutics Plc is a biotechnology company focused on developing innovative therapies using its proprietary Bicycle technology platform.
Company Address: Blocks A & B, Portway Building, Granta Park Great Abington, Cambridge, 0
Company Phone Number: 1223 261503 Stock Exchange / Ticker: NASDAQ BCYC
|
1.75% 
100 %